In Vitro Analysis of Hepatic Stellate Cell Activation influenced by Transmembrane 6 superfamily 2 Polymorphism

Songyao Liu[1,2], Eisuke Murakami[1,2], Takashi Nakahara[1,2], Kazuki Ohya[1,2], Yuji Teraoka[1,2], Grace Naswa Makokha[1,2], Takuro Uchida[1,2], Kei Morio[1,2], Hatsue Fujino[1,2], Atsushi Ono[1,2], Masami Yamauchi[1,2], Tomokazu Kawaoka[1,2], Daiki Miki[1,2], Masataka Tsuge[1,2,3], Akira Hiramatsu[1,2], Hiromi Abe-Chayama[1,2,4], C. Nelson Hayes[1,2], Michio Imamura[1,2], Hiroshi Aikata[1,2] and Kazuaki Chayama[1,2,5] *

[1] Department of Gastroenterology and Metabolism, Graduate School of Life Science, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima 734-8551, Japan

[2] Liver Research Project Center, Hiroshima University, Hiroshima 734-8551, Japan

[3] Natural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 739-0046, Japan.

[4] Center for Medical Specialist Graduate Education and Research, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.

[5] Institute of Physical and Chemical Research (RIKEN) Center for Integrative Medical Sciences, Yokohama 230-0045, Japan

**** Corresponding Author:***

Prof. Kazuaki Chayama, MD, PhD

Department of Gastroenterology and Metabolism, Graduate school of Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University

1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan

Tel: +81-82-257-5190, Fax: +81-82-255-6220

E-mail: chayama@hiroshima-u.ac.jp

Running title:

Liu et al: HSC activation influenced by TM6SF2 polymorphism (59 characters)

Word count:

Abstract: 213 words

Main text (Abstract, Introduction, Material and Methods, Results, Discussion, Acknowledgments, Reference and Figure legends): 4,251 words

References: 29

Figure and Tables: 3 Figures and 0 Tables

Abbreviations:

HCS; hepatic stellate cell, TM6SF2; Transmembrane 6 superfamily 2, TGFβ1; transforming growth factor beta 1, αSMA; alpha-smooth muscle actin, SNP; single nucleotide polymorphism

Key words (5):

hepatic stellate cell, liver fibrosis, non-alcoholic steatohepatitis, single nucleotide polymorphism, tm6sf2

Abstract

Non-alcoholic steatohepatitis (NASH) may progress via liver fibrosis along with hepatic stellate cell (HSC) activation. A single nucleotide polymorphism (SNP; *rs58542926*) located in *Transmembrane 6 superfamily 2* (*TM6SF2*) is reported to be significantly associated with fibrosis in NASH patients, but the precise mechanism is still unknown. This study aimed to explore the role of TM6SF2 in HSC activation *in vitro*. Plasmids producing TM6SF2 wild

type (WT) and mutant type (MT) containing E167K amino acid substitution were constructed, and the activation of LX-2 cells was analyzed by overexpressing or knocking down TM6SF2 under transforming growth factor beta 1 (TGFβ1) treatment. Intracellular alpha-smooth muscle actin (αSMA) expression in LX-2 cells was significantly repressed by TM6SF2-WT overexpression and increased by TM6SF2 knockdown. Following treatment with TGFβ1, αSMA expression was restored in TM6SF2-WT overexpressed LX-2 cells and was enhanced in TM6SF2 knocked-down LX-2 cells. Comparing αSMA expression under TM6SF2-WT or -MT overexpression, expression of αSMA in TM6SF2-MT overexpressed cells was higher than that in TM6SF2-WT cells and was further enhanced by TGFβ1 treatment. We demonstrated that intracellular αSMA expression in HCS was negatively regulated by TM6SF2 while the E167K substitution released this negative regulation and led to enhanced HSC activation by TGFβ1. These results suggest that the SNP in TM6SF2 might relate to sensitivity of HSC activation.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is becoming one of the most prevalent chronic liver diseases in modern countries, increasing rapidly as a result of recent upward trends in obesity and life-style changes (1). A subset of NAFLD patients go on to develop non-alcoholic steatohepatitis (NASH) by progression of steatosis and necro-inflammatory changes in the liver, leading to an increase in the incidence of hepatocellular carcinoma (2). Mortality in NAFLD patients has been reported to be independently associated with the stage of liver fibrosis (3), and it is important to prevent the progression of liver fibrosis in NAFLD patients. Recently, several drugs have been developed and have entered phase 2 or 3 clinical trials, but no effective drugs against NAFLD are yet available. Therefore, it is important to clarify the mechanism of liver fibrosis in NAFLD in order to identify therapeutic targets.

To identify clinical factors associated with the progression of liver fibrosis in

NAFLD patients, several genome wide association studies (GWAS) have recently been performed worldwide. A single nucleotide polymorphism (SNP) at *rs738409* in *patatin-like phospholipase domain containing 3* (*PNPLA3*) was identified as having strong associations with prevalence and disease progression in NAFLD and NASH (4) (5) (6) (7). A SNP in *transmembrane 6 superfamily 2* (*TM6SF2*) was also identified as a potential contributor to NAFLD pathogenesis (8) (9). The SNP *rs58542926* in *TM6SF2* is significantly associated with incidence of NAFLD and with fibrosis stage (10) (11) (12) (13). TM6SF2 protein is highly expressed in the small intestine and liver and plays a role in lipid synthesis and secretion of triglyceride-rich lipoproteins in the liver (14) (15) (16) (17) (18) (19). *TM6SF2 rs58542926* (C>T), a coding SNP that causes an amino acid substitution at codon 167 (E167K), is considered to lead to a loss of function and to accelerate hepatic steatosis (20). However, although lipids are metabolized in hepatocytes and may accumulate in these cells, liver fibrosis is strongly associated with hepatic stellate cells (HSCs) (21). The influence of the coding SNP in *TM6SF2* on the function of HSCs has not been clarified.

HSCs are normally activated in response to stimulation by inflammatory cytokines, such as transforming growth factor beta 1 (TGFβ1), and by pathogen-associated molecular patterns, such as lipopolysaccharides (21). Activated HSCs transform into myofibroblasts, and alpha-smooth muscle actin (αSMA) expression is up-regulated in the transformed myofibroblasts (21) (22). Activation of HSCs leads to secretion of extra-cellular matrix proteins such as collagen type 1 into the sinusoids, resulting in collagen accumulation and progression of liver fibrosis (21) (23). Although the impacts of genetic factors on clinical features of NAFLD and hepatocyte functions have been analyzed, the impacts of genetic factors on HSCs have not been examined. In the present study, we explored the role of *TM6SF2* SNP *rs58542926* in liver fibrosis using an *in vitro* activated HSC model.

Experimental Procedures

Construction of TM6SF2 expression plasmids

Human *TM6SF2* mRNA was amplified from LX-2 cells and cloned into p3xFLAG-CMV-10 vector (Sigma-Aldrich, Tokyo, Japan). The cloned plasmid containing the wild-type CC genotype at rs58542926 in *TM6SF2* gene was designated as p3FLAG/TM6SF2-WT. Subsequently, a modified plasmid, designated as p3FLAG/TM6SF2-MT, was generated by introducing a C-to-T point mutation at rs58542926 in *TM6SF2* to create an amino acid substitution [glutamic acid (E) to lysine (K)] in the TM6SF2 gene using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, Palo Alto, CA).

Cell culture

LX-2 cells from a human hepatic stellate cell line, which were provided by Dr. Mutsumi Miyauchi (Hiroshima University, Hiroshima, Japan), were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum at 37°C and under 5% CO_2. Mycoplasma testing was done before and after the experiment.

Each TM6SF2 expression plasmid was transiently transfected into LX-2 cells by FuGENE HD Transfection Reagent (Promega, Tokyo, Japan) in accordance with the instructions supplied by the manufacturer. Twenty-four hours after transfection, transfected cells were stimulated with 10 ng/ml of TGFβ1 for 48 hours, and then the cells were harvested and stored at -80°C until use.

Quantification of mRNA expression level

Total RNA was extracted from collected LX-2 cells using RNeasy Mini Kit (Qiagen, Chatsworth, CA) and reverse-transcribed using ReverTra Ace (TOYOBO, Osaka, Japan) and random primer in accordance with the instructions supplied by the manufacturer. αSMA or *TM6SF2* mRNA levels were quantified from the resulting cDNA by quantitative PCR using

the 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA), with the expression of GAPDH serving as a control. Expression levels were compared using the Wilcoxon signed-rank test. Amplification was performed in a 25 μl reaction mixture containing 12.5 μl SYBR Green PCR Master Mix (Applied Biosystems), 5 pmol of forward primer, 5 pmol of reverse primer, and 1 μl of cDNA solution. After incubation for 2 min at 50 °C, the sample was denatured for 10 min at 95 °C, followed by a PCR cycling program consisting of 40 cycles of 15 s at 95 °C, 30 s at 55 °C and 60 s at 60 °C. The following primer sequences were used: αSMA; 5'- CTCATTTTCAAAGTCCAGAGCTACA -3' and 5'-AGCGTGGCTATTCCTTCGT-3', TM6SF2; 5'-TGAAGCCCACCACATAGCTG-3' and 5'-CGGTCTACAGCTTGTCCCAT-3' , GAPDH; 5'- GAAGGTGAAGGTCGGAGTC -3' and 5'- GAAGATGGTGATGGGATTTC-3'.

Automated capillary Western blotting

LX-2 cells, transfected with TM6SF2 expression plasmids and treated with TGFβ1, were cooled on ice and dissolved with RIPA-like buffer (50 mM Tris-HCl [pH 8.0], 0.1% SDS, 1% NP-40, 150 mM sodium chloride, and 0.5% sodium deoxycholate) containing protease inhibitor cocktail (Sigma). Cell lysates were transferred onto capillary western immunoassay using Wes system (ProteinSimple, San Jose, CA). The proteins were detected with anti-TM6SF2 rabbit polyclonal antibody (Thermo Fisher Scientific, Rockford, IL), anti-αSMA rabbit monoclonal antibody (Cell signaling Technology Japan, Tokyo, Japan), or anti-GAPDH rabbit polyclonal antibody (Santa Cruz Biotechnology, Dallas, TX), followed by anti-rabbit immunoglobulin (GE Healthcare). Signal intensities were quantified using Compass software (ProteinSimple, San Jose, CA) and were corrected by GAPDH.

Knockdown of TM6SF2 by siRNA treatment

TM6SF2 siRNA was designed by siDirect (http://sidirect2.rnai.jp) using the TM6SF2

mRNA sequence (NM_001001524) as a reference. The designed siRNA sequence was as follows: 5’- AAAAUUCCGGUAUCUCUUCCU -3’, 5’-GAAGAGAUACCGGAAUUUUGG -3’. Prepared siRNAs were transfected into LX-2 cells by electroporation using the Neon transfection system (Thermo Fisher Scientific) at 1,100 mV for 30 msec followed by 24-hour incubation with serum-free medium.

Immunocytochemistry

LX-2 cells that had been transfected with TM6SF2 expression plasmid or treated with siRNA were incubated for 48 hours were fixed with 4% (v/v) paraformaldehyde and stained with anti-TM6SF2 antibody. The bound antibodies were detected with an Alexa 594-conjugated antibody against rabbit IgG (1:2000) (Molecular Probes, Eugene, OR). Nuclei were counterstained with bisbenzimide H 33258 (Hoechst 33258; Abcam, Tokyo, Japan). The stained cells were examined using a Fluoview FV10i microscope (Olympus co., Tokyo, Japan). Fluorescence intensities of TM6SF2 were compared using the Mann-Whitney U test.

Statistical analysis

All experiments were performed in triplicate wells. All data are expressed as the mean ± standard deviation (SD) and are presented relative to control. Pairwise differences between groups were examined for statistical significance using the Mann–Whitney U test. Univariate or multivariable differences among three or more groups were estimated using one-way ANOVA or two-way ANOVA with Tukey's post-hoc multiple comparison test, respectively. P-values less than 0.05 were considered significant after adjustment for multiple testing. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 22.0 (IBM corp., Armonk, NY.).

Results

TM6SF2 regulates αSMA expression in LX-2 cells

To analyze the impact of *TM6SF2* on HSC activation, p3FLAG/TM6SF2-WT plasmid was transiently transfected into LX-2 cells, and the induction of alpha-smooth muscle actin (αSMA) level was compared. Although αSMA level was not changed by transfection with empty vector (mock), *αSMA* mRNA expression was significantly suppressed in the presence of TM6SF2 expression plasmids (one-way ANOVA; $P < 0.05$) (Figure 1A).

To verify this result, we also analyzed the association between *TM6SF2* and *αSMA* by knocking down TM6SF2. The siRNA targeted to *TM6SF2* was transfected into LX-2 cells by electroporation, and intracellular αSMA level was compared 24 hours after siRNA treatment. TM6SF2 protein expression in LX-2 cells was suppressed to 34.4% by treatment with siRNA (Figure 1B), and immunostaining of TM6SF2 exhibited the same results (Supplementary Figure 1, 2). αSMA expression in TM6SF2-knocked down cells was 1.5~2.0-fold elevated compared to control cells in both mRNA and protein levels (Figure 1C and 1D). A similar tendency was also observed in intracellular *COL1A1* (collagen type 1 alpha 1) expression measured by real time PCR (Supplementary Figure 3). These results suggest that TM6SF2 down-regulates αSMA expression in HSCs.

TM6SF2 suppresses αSMA induction by TGFβ1 in LX-2 cells

To analyze the influence of TM6SF2 on αSMA expression under TGFβ1 stimulation, changes in αSMA expression in LX-2 cells were compared after TGFβ1 treatment. LX-2 cells were transfected with p3FLAG/TM6SF2-WT plasmid. Twenty-four hours after transfection, the cells were treated with 10 ng/ml of TGFβ1 for 48 hours, and intracellular αSMA induction was analyzed by quantitative PCR. *αSMA* mRNA levels in TM6SF2-overexpressed LX-2 cells were significantly suppressed and failed to increase to control levels following TGFβ1 stimulation (Figure 2A). A similar tendency was also observed in the siRNA experiment. The αSMA expression level in TGFβ1-stimulated LX-2 cells were similar in TM6SF2-knock

down LX-2 cells, and the expression of αSMA was enhanced under TGFβ1 stimulation (Figure 2B). These results suggested that HSCs could be additionally activated via TGFβ1 stimulation under lower expression of TM6SF2.

The impact of TM6SF2 phenotype on αSMA induction

To analyze the impact of the substitution at TM6SF2 amino acid 167, αSMA expression was compared between LX-2 cells transfected with p3FLAG/TM6SF2-WT plasmid and with p3FLAG/TM6SF2-MT plasmid. α*SMA* mRNA expression in cells transfected with p3FLAG/TM6SF2-WT plasmid was lower than that with p3FLAG/TM6SF2-MT plasmid (Figure 3A, one-way ANOVA; $P < 0.05$). Similarly, αSMA protein expression was more than 50% suppressed following transfection with p3FLAG/TM6SF2-WT plasmid compared to transfection with p3FLAG/TM6SF2-MT plasmid (Figure 3B, one-way ANOVA; $P < 0.05$).

LX-2 cells that had been transfected with or without TM6SF2 expression plasmid were stimulated by TGFβ1, and intracellular αSMA induction was analyzed by quantitative PCR. Although αSMA mRNA levels were suppressed by TM6SF2 expression, αSMA expression level in TM6SF2 E167K isoform (p3FLAG/TM6SF2-MT)-overexpressed LX-2 cells recovered and reached levels similar to those of control or mock cells after TGFβ1 stimulation (Figure 3C). Cell transfection and TGFβ1 stimulation independently affected αSMA expression in LX-2 cells (two-way ANOVA; $P < 0.05$), and, in particular, overexpression of p3FLAG/TM6SF2-WT plasmid significantly affected αSMA expression (Tukey's post-hoc multiple comparison test; $P < 0.05$). A similar tendency was also observed in intracellular *COL1A1* expression estimated by real time PCR (Supplementary Figure 4). These results suggest that basal αSMA expression in HSCs with TM6SF2 wild type might be low but might be up-regulated by TGFβ1 to a much higher level than HSCs with the TM6SF2 E167K isoform.

Discussion

NAFLD and NASH are progressive liver diseases characterized by accumulation of fat in human hepatocytes and an increased risk of cirrhosis or hepatocellular carcinoma. The number of patients is increasing worldwide, accompanied by recent upward trends in obesity, westernized high-fat oral intake, gut dysbiosis, inadequate exercise, and comorbid metabolic disorders like diabetes mellitus (2) (24). To identify factors associated with NAFLD, clinical studies have concluded that the prevalence, prognosis, and progression or severity of disease is significantly associated with SNPs in *PNPLA3* (*rs738409*) and *TM6SF2* (*rs58542926*) (4) (5) (11) (25) (26). Several studies have shown that the *rs738409*SNP in *PNPLA3* causes a loss-of-function amino acid substitution (I148M) in *PNPLA3* that affects regulation of lipid droplets in human hepatocytes and retinol metabolism in human HSCs, resulting in positive modulation of HSC activation (27) (28). However, the functional impact of the coding SNP in *TM6SF2* has not been sufficiently clarified. Although it has been reported that TM6SF2 is highly expressed in the liver, kidney, brain, and small intestine and that the E167K amino acid substitution TM6SF2 (rs58542926) interferes with localization to the endoplasmic reticulum due to protein misfolding (14) (20), the association between the existence of the coding SNP in *TM6SF2* and activation of HSCs has not been fully elucidated.

We first analyzed the association between TM6SF2 and the activation of human HSCs. Intracellular αSMA mRNA expression in LX-2 cells was suppressed by TM6SF2 overexpression, and its expression was increased by knocking down TM6SF2 (Figure 1A and 1D). Since similar results were observed in the other experiments (Figure 2A and 2B), these data suggest that TM6SF2 negatively regulates HSC activation.

In the progression of liver fibrosis, it is well known that TGFβ1, secreted directly by HSCs or by activated Kupffer cells, could activate HSCs, triggering transformation of HSCs to myofibroblasts (22). Thus, we analyzed the impact of TM6SF2 on HSC activation via

TGFβ1 signaling. Although intracellular αSMA expression in both control cells and TM6SF2 over-expressed cells was significantly up-regulated by TGFβ1 treatment, αSMA expression in TM6SF2 over-expressed LX-2 cells was significantly lower than that in control LX-2 cells after TGFβ1 treatment (Figure 2A). Similar results were observed in TM6SF2 knock down cells (Figure 2B). A similar tendency was also observed in intracellular *COL1A1* expression measured using real time PCR (Supplementary Figure 3,4). These results indicate that lower TM6SF2 expression could activate HSCs and that TGFβ1 could enhance this HSC activation.

Subsequently, we analyzed the functional impact of the coding SNP in *TM6SF2 in vitro*. Normal HSCs have lipid droplets containing retinol. However, once HSCs are activated, lipid droplets are diminished, and retinyl ester is degraded in the endoplasmic reticulum (ER) in HSCs (29). Since the amino acid substitution (E167K) in TM6SF2 (rs58542926 SNP) causes TM6SF2 to fail to localize to the ER (18) (19), we propose that amino acid substitution E167K in TM6SF2 could induce HSC activation by disrupting homeostasis in the ER. When TM6SF2 wild type or mutant type (E167K) were overexpressed in LX-2 cells, intracellular αSMA in LX-2 cells that overexpressed wild type TM6SF2 decreased more than those that overexpressed mutant TM6SF2 (Figure 3). Furthermore, αSMA expression in TM6SF2-mutant-overexpressed LX-2 cells increased to similar levels as control LX-2 cells after treatment with TGFβ1. Although the precise regulation of TM6SF2 in HSCs could not be determined in this study, our results suggest that the TM6SF2 E167K isoform affects HSC sensitivity by enhancing the response to TGFβ1.

In this study, we demonstrated the impact of an amino acid substitution in TM6SF2 on liver fibrosis using LX-2 cells. Although the impact of this *TM6SF2* coding SNP on liver fibrosis might not be strong considering the hazard ratio calculated for this SNP by GWAS studies, we consider that these results could help to clarify the role of TM6SF2 and the impact of the *TM6SF2* SNP on the progression of liver fibrosis in NAFLD and NASH patients.

Conclusion

TM6SF2 negatively affects αSMA expression in HSCs, and the TM6SF2 E167K isoform associated with the *rs58542926* SNP might affect HSC activation sensitivity. These results suggest that TM6SF2 might play a role in the process of HSC activation and liver fibrosis in NASH.

Acknowledgments

Not applicable

Funding

This work was supported by Grants-in-Aid for scientific research and development from the Ministry of Health, Labor and Welfare and Ministry of Education Culture Sports Science and Technology (JSPS KAKENHI grant number 18K15814) and Japan Agency for Medical Research and Development (grant number JP20fk0210040). This work was also supported with Gilead Sciences Research Scholars Program in Liver Disease by Gilead Sciences, Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SL, EM and KC conceived the study. GNM, AO, DM and HAC made contributions to design of the experiment. SL, EM analyzed and interpreted the experiment data. TN, KO, YT, TU, KM, HF, MY, TK and AH were involved in analyzing the data and revising the manuscript.

MT, CNH, AO, DM, MI and HA contributed to the conception and acquisition of the data. MT and CNH were major contributors in editing the manuscript. KC revised the manuscript and gave the final approval of the version to be submitted. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable

Patient consent for publication

Not applicable

Competing interests

The authors declare none.

References

1. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018;68(2):268-79.
2. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
3. Angulo P, Kleiner DE, Dam-Larsen, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-97.
4. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5.
5. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis

identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324.

6. Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(3):325-34.
7. Hotta K, Yoneda M, Hyogo H, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet., 2010;11:172.
8. Sookoian S, Castaño GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology. 2015;61(2):515-25.
9. Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology. 2015;62(6):1742-56.
10. Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: a comprehensive review. World J Gastroenterol. 2015;21(39):11088-111.
11. Goffredo M, Caprio S, Feldstein AE, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology. 2016;63(1):117-25.
12. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014; 5:4309.
13. Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61(2):506-14.
14. Li TT, Li TH, Peng J, et al. TM6SF2: A novel target for plasma lipid regulation. Atherosclerosis, 2018;268:170-6.

15. O'Hare EA, Yang R, Yerges-Armstrong L, et al. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. Hepatology. 2017;65(5):1526-42.
16. Luukkonen PK, Zhou Y, Nidhina Haridas PA, et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. J Hepatol. 2017;67(1):128-36.
17. Prill S, Caddeo A, Baselli G, et al. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Sci Rep. 2019;9(1):11585.
18. Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A. 2014;111(24):8913-8
19. Smagris E, Gilyard S, BusuRay S, et al. Inactivation of TM6SF2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins. J Biol Chem. 2016;291(20):10659-76.
20. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46(4):352-6.
21. Li JT, Liao ZX, Ping J, et al. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol., 2008;43(6):419-28.
22. Dewidar B, Mayer C, Dooley S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells. 2019;8(11).1419
23. Carpino G, Morini S, Corradini G, et al. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37(5):349-56.
24. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179-85.

25. Eslam M, Mangia A, Berg T, et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64(1):34-46.
26. Sookoian S, Pirola CJ. Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes. Sci Rep. 2016;6:27718. doi: 10.1038/srep27718.
27. Pingitore P, Dongiovanni P, Motta BM, et al. PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Hum Mol Genet. 2016;25(23):5212-22.
28. Bruschi FV, Claudel T, Tardelli M, et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. Hepatology. 2017:65(6):1875-90.
29. Testerink N, Ajat M, Houweling M, et al. Replacement of retinyl esters by polyunsaturated triacylglycerol species in lipid droplets of hepatic stellate cells during activation. PLoS One. 2012;7(4):e34945.

Figure legends

Figure 1. TM6SF2 regulates αSMA expression in LX-2 cells

A) The cloned TM6SF2 expression plasmid (p3FLAG/TM6SF2-WT) and empty vector (Mock) were transiently transfected into LX-2 cells followed by 24 hours of incubation. Intracellular αSMA expressions were measured by quantitative PCR. The expression of GAPDH served as a control. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD.

B) Non-treated and TM6SF2 knocked-down LX-2 lysates were transferred onto an automated capillary western blot. Anti-TM6SF2 antibody or anti-GAPDH antibody were applied, followed by anti-rabbit immunoglobulin. Signal intensity was corrected by GAPDH and is shown in the bar graph. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD (*$P < 0.05$).

C) Intracellular αSMA expression, measured by quantitative PCR, was compared in

non-treated and TM6SF2 knocked-down LX-2 cells. GAPDH expression was used as a control. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD (*$P < 0.05$).

D) Non-treated and TM6SF2 knocked-down LX-2 lysates were transferred onto an automated capillary western blotting system. Anti-αSMA antibody or anti-GAPDH antibody were applied, followed by anti-rabbit immunoglobulin. Signal intensities were corrected by GAPDH and are shown in the bar graph. Experiments were performed in duplicate wells. All data are expressed as the mean ± SD (*$P < 0.05$).

Figure 2. TM6SF2 suppresses αSMA induction by TGFβ1 in LX-2 cells

A) The cloned TM6SF2 expression plasmid (p3FLAG/TM6SF2-MT) and empty vector (Mock) were transiently transfected into LX-2 cells followed by 24 hours of incubation. LX-2 cells were stimulated with or without 10 ng/ml of TGFβ1 for 48 hours. Intracellular αSMA expression was measured by quantitative PCR. The expression of GAPDH served as a control. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD (*$P < 0.05$).

B) Non-treated and TM6SF2 knocked-down LX-2 cells were stimulated with or without 10ng/mL of TGFβ1 for 48 hours and intracellular αSMA expression was compared via quantitative PCR. The expression of GAPDH served as a control. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD (*$P < 0.05$).

Figure 3. The impact of TM6SF2 phenotype on αSMA induction in LX-2 cells

A) The cloned TM6SF2 expression plasmid consisting of p3FLAG/TM6SF2-WT and p3FLAG/TM6SF2-MT and empty vector (Mock) were transiently transfected into LX-2 cells, followed by 24 hours of incubation. Intracellular αSMA expression was measured by quantitative PCR, with the expression of GAPDH serving as a control. Experiments were

performed in triplicate wells. All data are expressed as the mean ± SD.

B) Cloned TM6SF2 expression plasmids consisting of p3FLAG/TM6SF2-WT and p3FLAG/TM6SF2-MT and empty vector (Mock) were transiently transfected into LX-2 cells, followed by 24 hours of incubation. LX-2 lysates were transferred onto an automated capillary western blotting system. Anti-TM6SF2 antibody or anti-GAPDH antibody were applied, followed by anti-rabbit immunoglobulin. Signal intensity was corrected by GAPDH, as shown in the bar graph. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD.

C) Cloned TM6SF2 expression plasmids consisting of p3FLAG/TM6SF2-WT and p3FLAG/TM6SF2-MT and empty vector (Mock) were transiently transfected into LX-2 cells, followed by 24 hours of incubation. LX-2 cells were stimulated with or without 10 ng/ml of TGFβ1 for 48 hours. Intracellular αSMA expression was measured by quantitative PCR, with GAPDH as a control. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD.

Figure 1.



Figure 2.

A)



B)



Figure 3.

A)



B)



Figure 3.

C)



Supplementary Figure 1.



Supplementary Figure 2.



Supplementary Figure 3.



Supplementary Figure 4.



Supplementary Figure 1. Fluorescence intensities of TM6SF2 in LX-2 cells

Non-treated and TM6SF2 knockdown LX-2 were stained with anti-TM6SF2 monoclonal antibody. The bound antibodies were detected with an Alexa 594-conjugated antibody against rabbit IgG. Fluorescence intensities of TM6SF2 were shown in box-whisker plot (*$P < 0.05$).

Supplementary Figure 2. Immunostaining of TM6SF2 LX-2 cells

Non-treated and TM6SF2 knockdown LX-2 were stained with anti-TM6SF2 monoclonal antibody. The bound antibodies were detected with an Alexa 594-conjugated antibody (red) against rabbit IgG. Nuclei were counterstained with bisbenzimide H 33258 (blue).

Supplementary Figure 3. TM6SF2 regulates COL1A1 expression in LX-2 cells

Intracellular COL1A1 (collagen type 1 alpha 1) expression, measured by quantitative PCR, was compared in non-treated and TM6SF2 knocked-down LX-2 cells. GAPDH expression was used as a control. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD (*$P < 0.05$).

Supplementary Figure 4. The impact of TM6SF2 phenotype on COL1A1 induction in LX-2 cells

The cloned TM6SF2 expression plasmid consisting of p3FLAG/TM6SF2-WT and p3FLAG/TM6SF2-MT were transiently transfected into LX-2 cells, followed by 24 hours of incubation. TM6SF2 overexpressing or non-treated LX-2 cells were stimulated with or without 10ng/mL of TGFB for 48 hours and compared by intracellular COL1A1 expressions measured by quantitative PCR. The expression of GAPDH served as a control. Experiments were performed in triplicate wells. All data are expressed as the mean ± SD.

SPANDIDOS PUBLICATIONS UK LTD

5-6 Kings Street Cloisters
Clifton Walk
London W6 0GY
Tel +44 (0)20 7262 8050
Fax +44 (0)20 7262 9825
Registered Number 7341977 England

1-2-3 Kasumi,
Minami-ku,
Hiroshima City,
Hiroshima,
Japan
Dept. of Gastroenterology and Metabolism,
Hiroshima Univ.

September 29, 2020

Our reference: 254410
Journal: Molecular Medicine Reports
Title: In Vitro Analysis of Hepatic Stellate Cell Activation influenced by Transmembrane 6 superfamily 2 Polymorphism
Authors: Mr Songyao Liu, Dr Eisuke Murakami, Dr Takashi Nakahara, Dr Kazuki Ohya, Dr Yuji Teraoka, Dr Makokha Grace Naswa, Dr Takuro Uchida, Dr Kei Morio, Dr Hatsue Fujino, Dr Atsushi Ono, Dr Masami Ymauchi, Dr Tomokazu Kawaoka, Dr Daiki Miki, Dr Masataka Tsuge, Dr Akira Hiramatsu, Dr Hiromi Abe-Chayama, Dr Nelson Clair Hayes, Dr Michio Imamura, Dr Hiroshi Aikata, Professor Kazuaki Chayama

Dear Song'yao Liu,

Thank you for your submission. The manuscript 'In Vitro Analysis of Hepatic Stellate Cell Activation influenced by Transmembrane 6 superfamily 2 Polymorphism' by Liu et al was provisionally accepted for publication in Molecular Medicine Reports on September 08, 2020. The submission should be considered to be formally accepted upon the receipt of proofs.

An author PDF file will be provided on publication.

Yours Sincerely,

Demetrios A. Spandidos

SPANDIDOS PUBLICATIONS UK LTD
5-6 KING STREET CLOISTERS
LONDON, W6 0GY, UNITED KINGDOM
VAT: 996278548
TEL: +442072628050 FAX: +442072629825